Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Cooper

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Lung Cancer (Amsterdam, Netherlands)|November 13, 2015
HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinibBob T Li, Adrian Lee, Sandra O'Toole, et al.
JAMA Oncology|December 23, 2017
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.
Investigational New Drugs|October 18, 2011
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumorsAndrea Wang-Gillam, William P Tew, Mace L Rothenberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 10, 2026
Update on pleural epithelioid mesothelioma: New insights for diagnosis and patient managementFrancoise Galateau Sallé, Mary Beth Beasley, Luka Brcic, et al.
Clinical & Translational Immunology|July 21, 2020
Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibodyZiduo Li, Edward Abadir, Kenneth Lee, et al.
The European Respiratory Journal|January 18, 2020
Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registryAlan K Y Teoh, Helen E Jo, Daniel C Chambers, et al.
Future Oncology (London, England)|July 30, 2019
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancerRachel Woodford, Yanni Loh, Joanna Lee, et al.
The New Phytologist|December 13, 2023
Shifts in internal stem damage along a tropical precipitation gradient and implications for forest biomass estimationHabacuc Flores-Moreno, Abbey R Yatsko, Alexander W Cheesman, et al.
Cancer Chemotherapy and Pharmacology|May 21, 2005
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumorsHiroyuki Kobayashi, S Gail Eckhardt, Jennifer A Lockridge, et al.
American Journal of Respiratory and Critical Care Medicine|June 16, 2015
A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural MesotheliomaSteven C Kao, Michael Fulham, Kirby Wong, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Lung Cancer (Amsterdam, Netherlands)|November 13, 2015
HER2 insertion YVMA mutant lung cancer: Long natural history and response to afatinibBob T Li, Adrian Lee, Sandra O'Toole, et al.
JAMA Oncology|December 23, 2017
Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.
Investigational New Drugs|October 18, 2011
A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumorsAndrea Wang-Gillam, William P Tew, Mace L Rothenberg, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 10, 2026
Update on pleural epithelioid mesothelioma: New insights for diagnosis and patient managementFrancoise Galateau Sallé, Mary Beth Beasley, Luka Brcic, et al.
Clinical & Translational Immunology|July 21, 2020
Targeting CD83 in mantle cell lymphoma with anti-human CD83 antibodyZiduo Li, Edward Abadir, Kenneth Lee, et al.
The European Respiratory Journal|January 18, 2020
Blood monocyte counts as a potential prognostic marker for idiopathic pulmonary fibrosis: analysis from the Australian IPF registryAlan K Y Teoh, Helen E Jo, Daniel C Chambers, et al.
Future Oncology (London, England)|July 30, 2019
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancerRachel Woodford, Yanni Loh, Joanna Lee, et al.
The New Phytologist|December 13, 2023
Shifts in internal stem damage along a tropical precipitation gradient and implications for forest biomass estimationHabacuc Flores-Moreno, Abbey R Yatsko, Alexander W Cheesman, et al.
Cancer Chemotherapy and Pharmacology|May 21, 2005
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumorsHiroyuki Kobayashi, S Gail Eckhardt, Jennifer A Lockridge, et al.
American Journal of Respiratory and Critical Care Medicine|June 16, 2015
A Significant Metabolic and Radiological Response after a Novel Targeted MicroRNA-based Treatment Approach in Malignant Pleural MesotheliomaSteven C Kao, Michael Fulham, Kirby Wong, et al.
Pageof 5